MetLife (MET) Stock Forecast & Price Target

Q: What analysts cover MetLife?

MetLife has been rated by research analysts at Argus , Barclays , Evercore , Jefferies Financial Group , JPMorgan Chase & Co. , Keefe, Bruyette & Woods , Mizuho , Morgan Stanley , Piper Sandler , TD Cowen , UBS Group , Weiss Ratings , and Wells Fargo & Company in the past 90 days.

$103.61 +1.43 (+1.40%)

Closing price 10/22/2026 03:59 PM Eastern

Extended Trading

$103.28 -0.33 (-0.32%)

As of 10/22/2026 07:52 PM Eastern

Compare

MetLife - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 15 Analyst Ratings

Sell
0

Hold
2

Buy
13

Based on 15 Wall Street analysts who have issued ratings for MetLife in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 2 have given a hold rating, and 13 have given a buy rating for MET.

Consensus Price Target

$105.44
1.76% Upside

According to the 15 analysts' twelve-month price targets for MetLife, the average price target is $105.44. The highest price target for MET is $115.00, while the lowest price target for MET is $80.00. The average price target represents a forecasted upside of 1.76% from the current price of $103.61.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for MET and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for MetLife and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MET Analyst Ratings Over Time

Type	Current Forecast 10/23/25 to 10/23/26	1 Month Ago 9/23/25 to 9/23/26	3 Months Ago 7/25/25 to 7/25/26	1 Year Ago 10/23/24 to 10/23/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	13 Buy rating(s)	13 Buy rating(s)	12 Buy rating(s)	9 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$105.44	$103.06	$99.00	$95.18
Forecasted Upside	1.76% Upside	6.14% Upside	4.58% Upside	21.76% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

MET Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MET Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

MetLife Stock vs. The Competition

Type	MetLife	Finance Companies	Broader Market
Consensus Rating Score	2.87	2.28	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	1.76% Upside	37.06% Upside	15.78% Upside
News Sentiment Rating	Positive News See Recent MET News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Show

Rating

Upside/Downside

Action

Report Date

0 Results

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/21/2026	TD Cowen 3 of 5 stars	Andrew Kligerman Not Rated	Boost Target	Buy	$110.00 ➝ $114.00	+11.69%
10/15/2026	JPMorgan Chase & Co. 3 of 5 stars	Pablo Singzon Not Rated	Boost Target	Overweight	$108.00 ➝ $110.00	+11.30%
10/12/2026	Wells Fargo & Company 3 of 5 stars	Wesley Carmichael Not Rated	Boost Target	Overweight	$109.00 ➝ $110.00	+10.59%
10/7/2026	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Yaron Kinar Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Outperform	$112.00 ➝ $109.00	+13.45%
10/7/2026	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Alex Scott Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Overweight	$97.00 ➝ $111.00	+14.17%
10/6/2026	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Michael Ward Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Buy	$105.00 ➝ $110.00	+13.44%
9/22/2026	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Paul Newsome Subscribe to MarketBeat All Access to unlock analyst rankings	Upgrade	Neutral ➝ Overweight	$99.00 ➝ $110.00	+13.71%
9/11/2026	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings		Reiterated Rating	Buy (B)
9/2/2026	Argus Subscribe to MarketBeat All Access to unlock brokerage rankings		Boost Target	Buy	$93.00 ➝ $109.00	+9.16%
8/24/2026	Evercore Subscribe to MarketBeat All Access to unlock brokerage rankings		Reiterated Rating	Mixed
Get the Latest News and Ratings for MET and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for MetLife and its competitors with MarketBeat's FREE daily newsletter.
8/24/2026	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Nigel Dally Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Overweight	$103.00 ➝ $111.00	+16.15%
8/11/2026	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access to unlock brokerage rankings	Ryan Krueger Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Outperform	$105.00 ➝ $108.00	+11.39%
8/10/2026	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Suneet Kamath Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Buy	$103.00 ➝ $115.00	+15.17%
7/15/2026	Atlantic Securities Subscribe to MarketBeat All Access to unlock brokerage rankings		Set Target		$103.00	+11.65%
7/15/2026	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings	Joshua Shanker Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Buy	$106.00 ➝ $103.00	+3.15%
5/15/2026	BMO Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings		Boost Target	Market Perform	$78.00 ➝ $80.00	-19.88%
2/6/2026	Wolfe Research Subscribe to MarketBeat All Access to unlock brokerage rankings		Lower Target	Outperform	$91.00 ➝ $89.00	-10.87%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 01:04 AM ET.

Should I Buy MetLife Stock? MET Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, October 19, 2026. Please send any questions or comments about these MetLife pros and cons to contact@marketbeat.com.

MetLife
Bull Case

Here are some ways that investors could benefit from investing in MetLife, Inc.:

MetLife, Inc. recently hit a new 52-week high of $102.43, with the stock currently trading at $99.66, reflecting strong momentum and a consensus rating of Moderate Buy from fifteen ratings firms that have assigned a consensus price target of $105.06, suggesting potential upside for investors.
The company demonstrated strong financial performance in its most recent quarter, reporting earnings per share of $2.43, which exceeded the consensus estimate of $2.30, and achieved a return on equity of 23.39%, indicating efficient use of shareholder capital and robust profitability.
MetLife, Inc. has a low beta of 0.78, meaning its stock price tends to be less volatile than the overall market, making it an attractive option for investors seeking stability and lower risk exposure during periods of market uncertainty.
The company offers a dividend yield of 2.35%, with a recent quarterly dividend of $0.5925 per share, providing a steady income stream for investors, supported by a sustainable dividend payout ratio of 45.40%.
MetLife, Inc. has approved a $3.00 billion share buyback plan, which allows the company to repurchase up to 4.8% of its shares, signaling management's confidence in the stock's undervaluation and potentially boosting earnings per share for remaining shareholders.

MetLife
Bear Case

Investors should be bearish about investing in MetLife, Inc. for these reasons:

MetLife, Inc. reported revenue of $13.52 billion for the most recent quarter, which fell significantly short of analysts' expectations of $19.67 billion, raising concerns about the company's ability to meet revenue targets and potentially impacting future growth prospects.
The company has a current ratio of 0.20 and a quick ratio of 0.20, indicating limited liquidity to cover short-term liabilities, which could pose financial risks if the company faces unexpected cash flow challenges or economic downturns.
MetLife, Inc. has a debt-to-equity ratio of 0.52, suggesting a moderate level of leverage that could increase financial risk, particularly if interest rates rise or the company's earnings decline, potentially affecting its ability to service debt.
Some institutional investors, such as BDF Gestion, have reduced their positions in MetLife, Inc. by 33.1% in the third quarter, indicating a lack of confidence from certain large investors and potentially signaling broader market skepticism about the stock's future performance.
MetLife, Inc. operates in the insurance industry, which is subject to regulatory changes and economic cycles, and the company's revenue growth of 10.5% year-over-year may not be sufficient to offset potential headwinds from increased competition or changing consumer preferences in the financial services sector.

MET Forecast - Frequently Asked Questions

According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for MetLife is $105.44, with a high forecast of $115.00 and a low forecast of $80.00.

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MetLife in the last year. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MET shares.

According to analysts, MetLife's stock has a predicted upside of 1.76% based on their 12-month stock forecasts.

Over the previous 90 days, MetLife's stock had 1 upgrade by analysts.

MetLife has been rated by research analysts at Argus, Barclays, Evercore, Jefferies Financial Group, JPMorgan Chase & Co., Keefe, Bruyette & Woods, Mizuho, Morgan Stanley, Piper Sandler, TD Cowen, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like MetLife more than other "finance" companies. The consensus rating for MetLife is Moderate Buy while the average consensus rating for "finance" companies is Hold. Learn more on how MET compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With MetLife Recommendations

MarketBeat monitors more than a dozen sources for MetLife analyst ratings, with the most recent rating issued on 10/21/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MetLife (MET) Stock Forecast & Price Target